Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABA <sub>B</sub> R Antibodies
Anna Rada, Anne Hagemann, Charlotte Aaberg Poulsen, Tobias Baumgartner, Tímea Berki, Morten Blaabjerg, Juliëtte Brenner, Jeffrey W. Britton, Andrew Christiana, Nicolás Lundahl Ciano-Petersen, Yvette S. Crijnen, Martin Elišák, Antonio Farina, A. Friedman, Zsófia Hayden, Julien Hébert, Martin Holtkamp, Zhen Hong, Jérôme Honnorat, M Feldmann, Sarosh R. Irani, Stjepana Kovac, Petr Marusič, Sergio Muñiz‐Castrillo, Sudarshini Ramanathan, Kelsey M. Smith, Claude Steriade, Christine Strippel, Rainer Surges, Maarten J. Titulaer, Christopher Uy, Juna M. de Vries, Christian G. Bien, Ulrich Specht
Abstract
BACKGROUND AND OBJECTIVES: R). We hypothesized that after a seizure-free period of 3 months, patients with AIE have a seizure recurrence risk of <20% during the subsequent 12 months. This would render them eligible for noncommercial driving according to driving regulations in several countries. METHODS: R-AIE, who had been seizure-free for ≥3 months. We used Kaplan-Meier (KM) estimates for the seizure recurrence risk at 12 months for each antibody group and tested for the effects of potential covariates with regression models. RESULTS: R. DISCUSSION: Taking a <20% recurrence risk within 12 months as sufficient, patients with NMDAR-AIE and LGI1-AIE could be considered eligible for noncommercial driving after having been seizure-free for 3 months.